Veradermics announced the closing of a $75 million Series B financing, led by Suvretta Capital Management and Longitude Capital. The financing will be used to fund the ongoing pivotal clinical development of Veradermics’ lead candidate VDPHL01 for the treatment of androgenetic alopecia (AGA) or pattern hair loss (PHL).

Veradermics, Inc. is a medical dermatology company advancing first-in-class therapeutics that address real-world patient needs in under-innovated dermatology markets.



Veradermics Names Reid Waldman As Chief Executive Officer

Description

Company Information

Related People

Executive Insights